Optimal Debulking Targets in Women With Advanced Stage Ovarian Cancer: A Retrospective Study of Immediate Versus Interval Debulking Surgery

Journal of Obstetrics and Gynaecology Canada

Volumn 34, Issue 6, 2012, Pages 558-566

  Altman, Alon D ^a   Nelson, Gregg ^b   Chu, Pamela ^b   Nation, Jill ^b   Ghatage, Prafull ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Gynaecologic surgery; Neoadjuvant treatment; Ovarian cancer; Residual tumour

Indexed keywords

ADULT; ADVANCED CANCER; ARTICLE; CANADA; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMEDIATE DEBULKING SURGERY; INTERVAL DEBULKING SURGERY; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME; COMPARATIVE STUDY; KAPLAN MEIER METHOD; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; TIME; UTERINE TUBE TUMOR;

DISEASE-FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84871892948     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)35272-0     Document Type: Article

References (33)

1. Canadian Cancer Statistics 2009. Available at: http://www.cancer.ca/Canada-wide/About%20cancer/Cancer%20statistics/~/media/CCS/Canada%20wide/Files%20List/English%20files%20heading/pdf%20not%20in%20 publications%20section/Stats%202009E%20Cdn%20Cancer.ashx. Accessed March 26, 2012.
2. Public Health Agency of Canada. Ovarian cancer in Canada. October 1999. Public Health Agency of Canada-Cancer Updates. Available at: . Accessed March 26, 2012. http://www.phac-aspc.gc.ca/publicat/updates/ovar-99-eng.php.
3. Wakabayashi M.T., Lin P.S., Hakim A.A. The role of cytoreductive/debulking surgery in ovarian cancer. J Natl Compr Canc Netw 2008, 6:803. 10;quiz 811.
4. Martinek I.E., Kehoe S. When should surgical cytoreduction in advanced ovarian cancer take place?. J Oncol 2010, 2010:852028.
5. Schorge J.O., Wingo S.N., Bhore R., Heffernan T.P., Lea J.S. Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer. Int J Gynaecol Obstet 2010, 108:123-127.
6. Vergote I., van Gorp T., Amant F., Leunen K., Neven P., Berteloot P. Timing of debulking surgery in advanced ovarian cancer. Int J Gynecol Cancer 2008, 18(Suppl 1):11-19.
7. Bristow R.E., Eisenhauer E.L., Santillan A., Chi D.S. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 2007, 104:480-490.
8. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002, 20:1248-1259.
9. Hunter R.W., Alexander N.D., Soutter W.P. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?. Am J Obstet Gynecol 1992, 166:504-511.
10. Harter P., Hilpert F., Mahner S., Kommoss S., Heitz F., Pfisterer J., et al. Prognostic factors for complete debulking in first- and second-line ovarian cancer. Int J Gynecol Cancer 2009, 19(Suppl 2):14-17.
11. Chi D.S., Eisenhauer E.L., Zivanovic O., Sonoda Y., Abu-Rustum N.R., Levine D.A., et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 2009, 114:26-31.
12. Tkacova M., Vertakova-Krakovska B., Belohorska B., Miskovska V., Helpianska L., Ondrus D., et al. Neo-adjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer treatment- a retrospective study [Article in Slovak]. Klin Onkol 2009, 22:273-277.
13. Vergote I., Trope C.G., Amant F., Kristensen G.B., Ehlen T., Johnson N., et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010, 363:943-953.
14. Suprasert P., Tiyanon J., Kietpeerakool C. Outcome of interval debulking in advanced ovarian cancer patients. Asian Pac J Cancer Prev 2008, 9:519-524.
15. du Bois A., Reuss A., Pujade-Lauraine E., Harter P., Ray-Coquard I., Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the arbeitsgemeinschaft gynaekologische onkologie studiengruppe ovarialkarzinom (AGO-OVAR) and the groupe d'investigateurs nationaux pour les etudes des cancers de l'ovaire (GINECO). Cancer 2009, 115:1234-1244.
16. Stuart G.C., Kitchener H., Bacon M., duBois A., Friedlander M., Ledermann J., et al. participants of 4th Ovarian Cancer Consensus Conference (OCCC); 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer. Report from the 4th Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 2011, 21:750-755.
17. Thigpen T., duBois A., McAlpine J., DiSaia P., Fujiwara K., Hoskins W., et al. First-line therapy in ovarian cancer trials. Int J Gynecol Cancer 2011, 21:756-762.
18. van der Burg M.E., van Lent M., Buyse M., Kobierska A., Colombo N., Favalli G., et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995, 332:629-634.
19. Giannopoulos T., Butler-Manuel S., Taylor A., Ngeh N., Thomas H. Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma. Eur J Gynaecol Oncol 2006, 27:25-28.
20. Rose P.G., Nerenstone S., Brady M.F., Clarke-Pearson D., Olt G., Rubin S.C., et al. Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004, 351:2489-2497.
21. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
22. Onda T., Yoshikawa H., Yasugi T., Matsumoto K., Taketani Y. The optimal debulking after neoadjuvant chemotherapy in ovarian cancer: proposal based on interval look during upfront surgery setting treatment. Jpn J Clin Oncol 2010, 40:36-41.
23. Gultekin M., Diribas K., Buru E., Dursun P., Yuce K., Ayhan A. Interval debulking in epithelial ovarian carcinomas: the past, present and the future. Eur J Gynaecol Oncol 2008, 29:242-245.
24. Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., Levine D.A., Poynor E.A., Aghajanian C., et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 2006, 103:1083-1090.
25. Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., Aghajanian C., Barakat R.R., Chi D.S. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol 2008, 108:276-281.
26. Kang S., Jong Y.H., Hwang J.H., Lim M.C., Seo S.S., Yoo C.W., et al. Is neo-adjuvant chemotherapy a "waiver" of extensive upper abdominal surgery in advanced epithelial ovarian cancer?. Ann Surg Oncol 2011, 18:3824-3827.
27. Vergote I., De Wever I., Tjalma W., Van Gramberen M., Decloedt J., van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998, 71:431-436.
28. Bristow R.E., Chi D.S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 2006, 103:1070-1076.
29. Le T., Alshaikh G., Hopkins L., Faught W., Fung M.F. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Ann Surg Oncol 2006, 13(12):1711-1716.
30. Bailly C., Bailly-Glatre A., Alfidja A., Vincent C., Dauplat J., Pomel C. Peritoneal carcinosis in ovarian cancer: conventional imaging (CT-scan and MRI). Bull Cancer 2009, 96:1155-1162.
31. Coakley F.V., Choi P.H., Gougoutas C.A., Pothuri B., Venkatraman E., Chi D., et al. Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology 2002, 223(2):495-499.
32. Gemer O., Gdalevich M., Ravid M., Piura B., Rabinovich A., Gasper T., et al. A multicentre validation of computerized tomography models as predictors of non-optimal primary cytoreduction of advanced epithelial ovarian cancer. Eur J Surg Oncol 2009, 35:1109-1112.
33. Shaaban A., Rezvani M. Ovarian cancer: detection and radiologic staging. Clin Obstet Gynecol 2009, 52(1):73-93.